Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus CyBorD versus CyBorD alone in newly diagnosed systemic AL amyloidosis
NL-OMON48611Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab in light-chain amyloidosis and plasma cell neoplasm (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall complete hematologic response rate. Started Jul 2018; status: recruiting.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosisplasma cell neoplasm
Beyond the preview
Go deeper on NL-OMON48611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48611.